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Abstract 21 
Human pharmaceuticals have been detected in wastewater treatment plants, rivers, and 22 
estuaries throughout Europe and the United States. It is widely acknowledged that there 23 
is insufficient information available to determine whether prolonged exposure to low 24 
levels of these substances is having an impact on the microbial ecology in such 25 
environments. In this study we attempt to measure the effects of exposing cultures of 26 
Pseudomonas putida KT2440 (UWC1) to six pharmaceuticals by looking at differences 27 
in metabolite levels. Initially, we used Fourier transform infrared (FT-IR) spectroscopy 28 
coupled with multivariate analysis to discriminate between cell cultures exposed to 29 
different pharmaceuticals. This suggested that on exposure to propranolol there were 30 
significant changes in the lipid complement of P. putida. Metabolic profiling with gas 31 
chromatography-mass spectrometry (GC-MS), coupled with univariate statistical 32 
analyses, was used to identify endogenous metabolites contributing to discrimination 33 
between cells exposed to the six drugs.  This approach suggested that the energy 34 
reserves of exposed cells were being expended and was particularly evident on exposure 35 
to propranolol. Adenosine triphosphate (ATP) concentrations were raised in P. putida 36 
exposed to propranolol. Increased energy requirements may be due to energy dependent 37 
efflux pumps being used to remove propranolol from the cell. 38 
39 
 3 
Introduction 40 
Studies spanning the last 20 years, have shown that human pharmaceuticals are present 41 
in waste water treatment plants (WWTPs), rivers and estuaries at the ng L-1 or low µg L-42 
1
 level throughout Europe and in the United States.1-9 In monitoring studies in the UK 13 43 
pharmaceuticals selected from priority lists of the UK Environment Agency and the 44 
Oslo and Paris Commission (OSPAR) were detected at concentrations ranging from 11 45 
– 69,570 ng L-1 in raw WWTP effluent 1.  46 
Wastewater from large industrial sites in India and China producing generic drugs in 47 
bulk for the global market has been shown to be a source of far higher environmental 48 
concentrations of pharmaceuticals10. Fick and colleagues showed contamination of 49 
surface, ground and drinking water in the Hyderabad drug-producing area, where 9 50 
drugs were detected in the mg L-1 range in two lakes and at high ng L-1  or low µg L-1 51 
levels in wells located in surrounding villages.11 The effluent from the WWTP serving 52 
approximately 90 bulk drug manufacturers shown to contain high levels of drugs with a 53 
range of vertebrate drug targets was toxic to aquatic vertebrates even at high dilutions, 54 
with 40% reduced growth in tadpoles in diluted (0.2%) effluent, and a median lethal 55 
concentration for zebrafish between 2.7-8.1%.12  56 
Pharmaceuticals merit concern as environmental pollutants because they are designed 57 
with high potency and high specificity for interaction with biological systems: they are 58 
of possible harm to the environment because they are designed to target specific 59 
receptors/enzymes, which may have homologs in other species. Although studies such 60 
as that of Gunnarsson et al.13 conclude that bacteria have both low numbers of 61 
homologs and low sequence similarity to those in man, many microbial organisms have 62 
an important environmental role which includes element cycling and the degradation of 63 
xenobiotic pollutants, and stress responses due to chronic exposure might impact on 64 
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fitness for survival. While Sumpter in his recent review14 concludes that the vast 65 
majority of pharmaceuticals will have no appreciable real-world environmental 66 
consequence it has been shown that pharmaceuticals have a range of acute and chronic 67 
toxicities on test organisms where environmental exposure is persistent at low 68 
concentrations.15, 16 It has been suggested that both concentration addition, where 69 
multiple compounds of the same class are present, each at low concentration, and 70 
response addition where multiple compounds of different classes are present, may cause 71 
stress responses in organisms and impact on fitness for survival.17-20 Environmental risk 72 
assessments (ERA) are now required when applying for marketing authorization for a 73 
medicinal product for human use in the European Union (EU) (Council Directive 74 
2001/83/EC as amended by Council Directive 2004/27/EC). In a tiered approach to 75 
testing, evaluation beyond acute toxicity tests is required where the predicted 76 
environmental concentration (PEC) of a pharmaceutically active compound is more than 77 
0.01 µg L-1. There is clearly a need to ascertain chronic effects of pharmaceuticals in the 78 
environment, and to mitigate pollution due to bulk drug manufacture. 79 
 80 
Here, we studied the effects of pharmaceutical exposure on Pseudomonas putida, a 81 
metabolically versatile soil bacterium, able to undertake important metabolic activities 82 
in the environment, including element cycling and the degradation of xenobiotic 83 
pollutants.21 P. putida strain KT2440 has been certified as a biosafety host for the 84 
cloning of foreign genes, and has potential for biotechnological applications such as 85 
bioremediation and biocatalysis.22 P. putida KT2440 UWC1 is a plasmid-free, 86 
restriction-negative, spontaneous rifampin-resistant derivative of P. putida KT2440.23 87 
Recent sequencing of the 6.1Mb genome of P. putida KT244024 has revealed diverse 88 
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metabolic and transport systems, with a comparatively high number of efflux pumps 89 
associated with protection against toxic substrates and metabolites.   90 
Metabolomics is a well-established field for the global analysis of endogenous 91 
metabolites within cells, tissue, biofluids, organs or whole organisms, and utilizes 92 
analytical techniques combined with statistical analysis. Where traditional studies may 93 
focus on one or a few biochemical pathways, discovery metabolomics attempts to 94 
observe global metabolite alterations. As such, discovery metabolomics is considered to 95 
be hypothesis generating, rather than hypothesis testing, with the possibility of finding 96 
novel results which should be tested further targeted experiments. Metabolomics offers 97 
several distinct advantages over other omic studies. A ten-fold difference is generally 98 
observed in the number of metabolites compared to the number of genes (fewer 99 
metabolites than genes), making the metabolome more amenable to both chemical 100 
analysis and data interpretation.25, 26 While alterations in the transcriptome or proteome 101 
may not always lead to changes in the metabolic phenotype27, the metabolome 102 
represents the final products of gene expression and is closest to the function or 103 
phenotype of the cell.  Furthermore, metabolic control analysis (MCA) has 104 
demonstrated that changes in concentration of metabolites can be observed even when 105 
alterations in the concentrations of transcripts and proteins are small.28 Metabolomics is 106 
a high-throughput strategy with low costs per analysis compared to transcriptomic and 107 
proteomic technologies, and, unlike other omics techniques, does not rely on species-108 
specific information. The reader is directed to the literature for information on the 109 
analytical technologies and methodologies29-36, and on the statistical approaches used in 110 
metabolomics.37 Environmental metabolomics has recently been defined as the 111 
application of metabolomics techniques to characterise the metabolism of free living 112 
organisms obtained from the natural environment and of organisms reared under 113 
 6 
laboratory conditions, where those conditions specifically serve to mimic scenarios 114 
encountered in the natural environment.38 There is considerable potential for omic 115 
profiling methods to progress significant advances in regulatory ecotoxicology, with 116 
applications including biomarker development and risk assessment for toxicant 117 
exposure, and evaluation of metabolic responses to environmental stressors.39, 40 118 
Reviews of recent applications in environmental metabolomics can be found in 41, 42.  119 
In whole organism fingerprinting FT-IR spectroscopy measures bond vibrations of 120 
functional chemical groups in cell constituents such as DNA and RNA, proteins, lipids 121 
and carbohydrates.  FT-IR may be used as a screening tool providing rapid 122 
discrimination between samples, through measurement of overall phenotypic changes in 123 
a sample without specific identification of the individual metabolites responsible. In 124 
contrast, metabolic profiling by GC-MS provides semi-quantification and, where 125 
possible, the definitive identification of metabolites through retention time and mass 126 
spectrum matching. Subsequent data analysis can then reveal discriminatory 127 
metabolites.33 128 
 129 
In this study we monitored the effect on the metabolism of P. putida KT2440 UWC1 of 130 
exposure to six pharmaceutical compounds; four analgesics (3 non-steroidal anti-131 
inflammatory drugs (NSAID) and acetaminophen - a possible COX -isoform inhibitor 132 
but with an ill-defined mechanism of action), and two β-adrenergic receptor agonists 133 
(Table SI3 1, Supplementary Information). Five of the compounds acetaminophen, 134 
diclofenac, ibuprofen, mefenamic acid and propranolol have been detected in 135 
wastewater treatment plant effluent in the UK.1 Acetaminophen was detected in raw 136 
effluent only at a mean concentration of 27,341 ng L-1, diclofenac throughout the 137 
treatment plant at concentrations ranging from 342-978 ng L-1, ibuprofen 3063-23,161 138 
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ng L-1, mefenamic acid 234-959 ng L-1 and propranolol 83-291 ng L-1. Roberts and 139 
Thomas suggest that it would also be beneficial to determine levels of parent 140 
compounds present in sewage sludge, in order to determine levels of adsorption.1 141 
 In this study we exposed P. putida KT2440 to the pharmaceuticals at a single 142 
concentration of 50 µg mL-1; although higher than measured environmental 143 
concentrations in the UK, this is a concentration well below the minimum inhibitory 144 
concentrations established for the pharmaceuticals, and at which we had seen a 145 
measurable effect in earlier experiments using FT-IR spectroscopy. We performed a 146 
principal components-canonical variates analysis on the FT-IR spectra of whole cells, 147 
and ANOVA and correlation analysis on the GC-MS profiles of the methanol cell 148 
extracts of P. putida exposed either to one of the pharmaceuticals or to water as a 149 
control. Metabolic fingerprinting by FT-IR spectroscopy suggested that on exposure to 150 
propranolol there were significant changes in the lipid complement of P. putida. 151 
Metabolic profiling from GC-MS measurements suggested that the energy reserves of 152 
exposed cells were being expended and this was particularly evident on exposure to 153 
propranolol. Therefore we measured adenosine triphosphate (ATP) concentrations in P. 154 
putida exposed to propranolol using a bioluminescence assay.  155 
 156 
Materials and Methods  157 
Materials and Methods for the experiment and for the statistical analysis are 158 
described in detail in the Supplementary Information. In preliminary experiments the 159 
effect of each pharmaceutical on growth of P. putida was determined, the minimum 160 
inhibitory concentration (MIC) of the pharmaceuticals for P. putida KT2440 UWC1 161 
was estimated, and the recovery of the pharmaceuticals was monitored by HPLC in 162 
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order to assess if there was any metabolism of the pharmaceuticals by P. putida over 24 163 
h.  For the metabolomics analysis, briefly, Pseudomonas putida KT2440 UWC1 was 164 
cultured, in replicate, in liquid medium supplemented with one of 6 drugs at a 165 
concentration of 50 µg mL-1, or water as a control. At the end of the exponential growth 166 
period cells were harvested and the sample split to provide cells for FT-IR spectroscopy 167 
and for GC-MS. Metabolite fingerprinting of whole cells by FT-IR spectroscopy was 168 
carried out according to a modified method of Goodacre et al..43 Metabolite profiling of 169 
methanol cell extracts by GC-MS was carried out according to a modified method of 170 
Winder et al.30 using GC-MS conditions optimized for yeast.44 ATP in methanol:water 171 
extracts of P. putida exposed to propranolol was measured using a bioluminescence 172 
assay kit available from Roche Molecular Biochemicals (Roche Diagnostics, Burgess 173 
Hill UK). Full details are given in the supplementary material. A combined principal 174 
components-canonical variates analysis (PC-CVA) was carried out for both the FT-IR 175 
spectra and GC-MS data using programs written in MATLAB45 as detailed elsewhere.46 176 
ANOVA was carried out on GC-MS data using programs written in MATLAB 177 
(http://www.mathworks.com/) and described elsewhere.37 Correlation analysis for 178 
metabolomics data is described by Steuer.47, 48 Correlation analysis for significantly 179 
altered metabolites was carried out using Graphviz open source graph visualization 180 
software 49 following an approach proposed by Kamada and Kawai. 50 Full details are 181 
given in the supplementary material.   182 
Results and Discussion 183 
Results for the determination of minimum inhibitory concentrations, the effect of each 184 
pharmaceutical on growth and monitoring recovery of the pharmaceuticals by HPLC are 185 
given in the Supplementary Information.  186 
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Multivariate Analysis of FT-IR Data: A total of 26 PCs were extracted for a cross-187 
validated PC-CVA model for the FT-IR spectra. Figure 1a shows the PC-CV score 1 188 
plotted against PC-CV score 2 for the FT-IR spectra of P. putida exposed to the six 189 
pharmaceuticals. In this analysis, the FT-IR spectra from 4 replicate cultures of P. 190 
putida were used as a training set, and the spectra from the fifth replicate were used as 191 
an independent test set with no a priori knowledge of the class structure. The test data 192 
should lie within the bounds of the training data, defined here as the 95% confidence 193 
limit from the group centres here constructed around each group mean by the χ2 194 
distribution on two degrees of freedom, as observed for P. putida exposed to ibuprofen 195 
and mefenamic acid. The cells exposed to propranolol and ibuprofen are separated, both 196 
from the control and cells exposed to the remaining pharmaceuticals, along PC-CV1, 197 
and those exposed to mefenamic acid along PC-CV2.  No effect on P. putida exposed to 198 
acetaminophen, atenolol or diclofenac was observed on inspection of the lower 199 
canonical variates (data not shown). Examination of the loadings for PC-CV1 from the 200 
PC-CV analysis (Figure 1b) shows, firstly, significantly high loadings occurring at 201 
several wavenumbers for propranolol at 1570, 1483, 1271, 1242, and 1102 cm-1. High 202 
loadings in the region corresponding to aliphatic C-H, and hence bacterial fatty acids, at 203 
2919 and 2850 cm-1 prompted us to investigate lipid alterations in P. putida exposed to 204 
propranolol.  There are also significantly high loadings in the regions corresponding to 205 
the amide I bands in protein structures at 1655cm-1 (α-helical structures), 1709, 1659 206 
and 1630 cm-1 (β-sheet structures).51 207 
 These observations, together with the reduction in free amino acids observed in the 208 
GC-MS analysis (vide infra) are consistent with the theory that cell integrity is 209 
maintained through cis-to-trans isomerization of membrane lipids which results in a 210 
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more rigid cell membrane structure, and synthesis of drug efflux pumps in order to 211 
remove toxic substances from the cell.52 212 
The PC-CVA was repeated using absorbances at wavenumbers selected from those with 213 
significantly high loadings shown in Figure 1b. Rebuilding the model with absorbances 214 
only at wavenumbers significant for bacterial fatty acids showed discrimination between 215 
P. putida exposed to propranolol and the control, and no discrimination of any other 216 
exposure from the control (Figure 2). Thus, observed lipid alterations were specific for 217 
exposure to propranolol. PC-CVA models built using absorbances at selected 218 
wavenumbers significant for the fingerprint region showed little difference from the 219 
model using the entire dataset, affording no new information, while there were too few 220 
wavenumbers significant for protein to use successfully in a PC-CVA model. 221 
 222 
(Figure 1) 223 
(Figure 2) 224 
 225 
Univariate Analysis of GC-MS Data: ANOVA was performed for P. putida exposed to 226 
each pharmaceutical versus the control using the family-wise error rate (FWER) to 227 
determine a suitable threshold for the p-value.53 Thresholds equivalent to α = 0.05 were 228 
determined for cells exposed to propranolol (0.0177), diclofenac (0.006), 229 
acetaminophen (0.005), atenolol (0.003) and mefenamic acid (1.76 x 10-4). A threshold 230 
was determined equivalent to α = 0.1 for cells exposed to ibuprofen (0.013), in order to 231 
be able to compare alterations in metabolites, since discrimination of these samples was 232 
earlier observed from the FT-IR data. A total of 76 metabolites were significantly 233 
altered overall with p-values below the FWER thresholds, and 67 of these had an area 234 
under the ROC curve54 > 0.85. Of these, 43 were altered on exposure to propranolol, 17 235 
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on exposure to diclofenac, 16 on exposure to ibuprofen, 14 on exposure to 236 
acetaminophen, 8 on exposure to atenolol, and 3 on exposure to mefenamic acid. 237 
Metabolites are listed in the supporting information (Table SI2 1.), together with the p-238 
value and fold difference in median GC-MS peak response. In order to view alterations 239 
which are common to exposure to the different pharmaceuticals, the 67 metabolites are 240 
ordered firstly by significance (p-value) for exposure to propranolol, followed by 241 
significance for exposure to diclofenac, ibuprofen, acetaminophen etc.  242 
Metabolite identification is currently recognised as a major limitation in GC-MS 243 
metabolomics studies, and a number of studies report metabolites of biological interest 244 
as unidentified.55 The accurate identification of metabolites requires the construction of 245 
mass spectral / retention index libraries. Commercially available GC–MS libraries such 246 
as NIST/EPA/NIH and Wiley have not been developed with the objective of including 247 
endogenous (or exogenous) metabolites, and are not widely applicable in metabolomics 248 
studies. A number of research groups have, therefore, developed their own metabolite 249 
libraries employing both the mass spectrum and retention index to define a metabolite, 250 
for example the Golm (http://csbdb.mpimp-golm.mpg.de/csbdb/gmd/gmd.html;56 and 251 
Feihn  (http://fiehnlab.ucdavis.edu/Metabolite-Library-2007/;57 databases. For definitive 252 
metabolite identification, comparison of fragmentation mass spectra with authentic 253 
chemical standards is required. Standards are often unavailable for endogenous 254 
metabolites and therefore only possible or probable identifications can be assigned in a 255 
large number of instances. In this study those metabolites where the identification is 256 
definitive are labeled with the metabolite name and an asterisk in the supplementary 257 
information, those where the identification is tentative labeled with the metabolite 258 
name, while unidentified metabolites are identified with a number. The recorded fold 259 
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difference is the median fold difference in GC-MS peak response (cells exposed to a 260 
pharmaceutical / control cells exposed to water). 261 
Altered metabolites in P. putida exposed to propranolol are visualised in Figure 3, 262 
where the area under the ROC curve is plotted versus the p-value from the ANOVA 263 
analysis.  Metabolites with an area under the ROC curve > 0.7 and a p-value < 2 x 10-2 264 
are labeled, and metabolites with an area under the ROC curve > 0.85, with p < 0.01 265 
were considered significant and selected for correlation analysis.  266 
(Figure 3) 267 
(Figure 4) 268 
Spring-embedded correlation plots for the significant metabolites identified from the 269 
ANOVA analysis show correlations in the cells exposed to water (Figure 4a) and 270 
correlations in the cells exposed to propranolol (Figure 4b). Correlation analyses for P. 271 
putida exposed to the other pharmaceuticals were not as informative as that for 272 
propranolol and are not shown; for example in P. putida exposed to ibuprofen 273 
correlations were observed only between trehalose and metabolites 35 and 47, and 274 
further to 2-aminoethyldihydrogenphosphate and tropic acid, and between cellobiose, 275 
putrescine, glycerol-3-phosphate a sugar alcohol and metabolite 95. 276 
 277 
In P. putida exposed to propranolol 9 metabolites identified with the low p-values in the 278 
ANOVA analysis (< 5.6 × 10-4) were raised in concentration from, or lowered in 279 
concentration to, near the analytical limit of detection in exposed cells (Figure SI3 2 in 280 
the supplementary information). All except metabolites 130 and 131 had an area under 281 
the ROC curve of 1, implying that these metabolites are entirely diagnostic of cells 282 
exposed to propranolol. Propranolol itself was present in the extracts of exposed cells 283 
and absent in the control cells. The concentration of metabolites 129 and 130 (for which 284 
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there was no definitive identification) fell below the limit of detection in exposed cells. 285 
Metabolite 129 was also altered significantly in cells exposed to diclofenac and 286 
mefenamic acid. Metabolites 131, 134, 135, 139, 142, and 145 were raised in exposed 287 
cells from near or below the limit of detection in the control, and were not present in 288 
cells exposed to any other pharmaceutical in the study. Identification was not possible 289 
from the mass spectra which contained only low m/z ions.  Further work using 13C-290 
labeled propranolol would determine whether propranolol is metabolized by P. putida, 291 
and whether metabolites 139, 134, 135, 142 and 145 are endogenous metabolites or 292 
products of propranolol catabolism.  293 
 294 
In P. putida exposed only to water, metabolite 130 is correlated with the amino acid 295 
valine, and correlation extends through other amino acids to trehalose and cellobiose. 296 
This correlation is disrupted within the sample set of P. putida exposed to propranolol 297 
as the concentration of metabolite 130 falls to near to the limit of detection. In cells 298 
exposed to propranolol the concentrations of trehalose and cellobiose are lowered by 0.5 299 
and 0.8, respectively, when compared to P. putida exposed only to water. In P. putida 300 
exposed to propranolol, propranolol itself is correlated to both trehalose and cellobiose 301 
and another energy related metabolite, a sugar phosphate, and correlation is extended 302 
from propranolol through cellobiose and metabolite 139 to succinic acid, a metabolite of 303 
the TCA cycle. Concentrations of sugar phosphates and succinic acid were raised, 1.3 - 304 
2.1 fold and 3 fold, respectively, in P. putida exposed to propranolol, suggesting 305 
increased glucose flux through glycolysis, as does utilization of trehalose and cellobiose 306 
(Figure 5). 307 
(Figure 5) 308 
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Glycolysis is primarily via the pentose phosphate and the Entner-Doudoroff pathways in 309 
Pseudomonas.58 Trehalose degradation to glucose is inferred in P. putida via the 310 
pathway trehalose degradation I, from its expected taxonomic range, in the MetaCyc 311 
database.59 We observed a 1.3 fold increase in xylitol in exposed cells indicative of 312 
pentose interconversions. 313 
 314 
Both trehalose and cellobiose were identified as significantly altered metabolites on 315 
exposure to more than one pharmaceutical: in P. putida exposed to propranolol, 316 
ibuprofen, acetaminophen and atenolol the concentration of trehalose was lowered 317 
significantly by 0.5, 0.4, 0.4, and 0.5; in P. putida exposed to propranolol and ibuprofen 318 
the concentration of cellobiose was also lowered significantly by 0.8 and 0.3, 319 
respectively. Trehalose has been observed to have a role as an osmoprotectant; for 320 
example trehalose concentration in P. aeruginosa was recently shown to be dependent 321 
on NaCl concentration60, and in response to solvent exposure in Pseudomonas sp. 322 
BCNU171.61 In this study the concentration of both trehalose and cellobiose were 323 
reduced and we inferred from these changes that the disaccharides trehalose and 324 
cellobiose, which have a role as an energy reserve (both converted to D-glucose), are 325 
utitilized as some energy consuming process(es) is (are) upregulated on exposure to 326 
propranolol. We confirmed that ATP concentrations were raised in P. putida exposed to 327 
propranolol (vide infra and Figure 6). Propranolol, which has a planar naphthalene 328 
structure and is known to interact with lipid membranes62, is present in the extracts of 329 
the exposed cells. It may be that an energy dependent efflux pump is one mechanism 330 
used to remove propranolol from the cell.  P. putida KT2440 genome sequencing24 331 
revealed a large number of different efflux systems that may be involved in the active 332 
export of solvents, and the TolC outer membrane channel protein has been shown to be 333 
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upregulated in response to phenol.63 Concurrent with solvent extrusion, a process with 334 
high energy demand partly required for the operation of efflux pumps, sugar uptake, 335 
glucose catabolic enzymes, and TCA cycle enzymes are induced.64 336 
 337 
Amino acids were reduced in concentration on exposure to propranolol by 0.29 – 0.73 338 
fold (Table SI3 2 in the supplementary information.). By contrast, few significant 339 
alterations in amino acids were observed on exposure to other pharmaceuticals. 340 
Alterations were observed on exposure to ibuprofen (phenylalanine: 1.2 fold increase), 341 
diclofenac (β-alanine: 0.73 fold decrease) and acetaminophen (phenylalanine: 0.2 fold 342 
decrease, and glutamic acid: 0.72 fold decrease). Together with alterations in the protein 343 
complement of exposed cells observed in the FT-IR analysis this is consistent with de 344 
novo protein synthesis (possibly including an efflux system) in response to exposure. 345 
Using DNA array technology to investigate the response of P. putida KT2440 to 346 
toluene, o-xylene and 3-methylbenzoate Dominguez-Cuevas and co-workers observed 347 
major changes in genes related to amino acid biosynthesis and critical functions for 348 
protein production.65 Strong induction of methionine biosynthesis was observed. In 349 
addition, leucine, isoleucine, tryptophan, serine and arginine biosynthesis was induced 350 
while catabolism of tryptophan and arginine was turned down, reflecting the need for 351 
amino acids in the new proteome found in cells exposed to toluene. 352 
 353 
In P. putida exposed to propranolol we observed a significant 0.66 fold decrease in 354 
myoinositol which has a role in glycosylphosphatidylinositol (GPI)-anchor biosynthesis, 355 
and the anchoring of cell-surface proteins to the cell membrane. 356 
 357 
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In P. putida exposed to propranolol we observed that the concentrations of 2-358 
monopalmitin and monostearin were lowered to near the analytical limit of detection 359 
and by 0.8, respectively. The level of octadecanoic acid was raised 8 fold, although the 360 
p-value from the ANOVA was marginally greater than the threshold p-value at 2.14 x 361 
10-2. We observed a significant 2 fold increase in levels of glycerol-3-phosphate which 362 
has a major role in glycerolipid and glycerophospholipid metabolism, where it is the 363 
precursor to the phosphatidyl moiety and the two phosphatidyl residues linked by a 364 
glycerol moiety in cardiolipins. We observed a significant 0.49 fold decrease in level of 365 
heptadecanoic acid decreased, and a slight increase (1.15 fold) in the level of 366 
pentadecanoic acid. Other fatty acids detected were hexadecanoic, hexadecenoic, cis-9-367 
octadecenoic acid, and octadecenoic acid methyl ester and were not altered significantly 368 
on exposure to propranolol. 369 
 370 
 In cells exposed to diclofenac, atenolol and mefenamic acid, the concentration of 9-371 
octadecenoic acid methyl ester fell to the analytical limit of detection, and hexadecenoic 372 
acid lowered by 0.9 in cells exposed to ibuprofen and may be indicative of 373 
cyclopropane fatty acid formation. The unsaturated fatty acids cis-9-octadecenoic, cis-374 
11-octadecenoic and cis-9-hexadecenoic acids are the precursors of the cyclopropane 375 
fatty acids found in E. coli and P. putida, cis-9,10- and cis-11,12-376 
methyleneoctadecanoic (C19) and cis-9,10-methylenehexadecanoic (C17) acids 66. 377 
However, methylation is to the esterified fatty acid in phospholipids (the C1 donor is S-378 
adenoyslmethionine), and, since the extraction protocol for GC-MS did not allow 379 
detection of fatty acids from esterified lipids, we were unable to detect any 380 
corresponding alterations in C19 or C17 cyclopropane fatty acids. The concentration of 381 
pentadecanoic acid increased 1.1 fold in cells exposed to ibuprofen and acetaminophen. 382 
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 383 
Ramos and colleagues summarized several alterations in fatty acid composition in the 384 
bacterial response to solvent exposure52, which include cis to trans isomerization of 385 
esterified fatty acids, a shift in the ratio of saturated : unsaturated fatty acids and 386 
formation of C17 cyclopropane fatty acids. Quantitative proteomics has revealed the 387 
upregulation of proteins involved in cell wall biosynthesis and plasma membrane fatty 388 
acids, and the outer membrane efflux protein TolC in the phenol-induced stress-389 
response in KT2440.63 The highest level of phenol-stimulation was observed for AccC-390 
1. This is the enzyme encoding the first step of the fatty acid biosynthetic pathway and 391 
leads to an increase in the rate of fatty acid biosynthesis under phenol stress as a 392 
recovery mechanism for oxidatively damaged membrane phospholipids.  393 
Propranolol is known to interact with lipid membranes and was observed in the 394 
methanol extracts of exposed cells. Tolerance to toluene in P. putida DOT-T1E has 395 
been suggested to be based on its exclusion by constitutive and inducible efflux pumps 396 
and rigidification of the cell membranes via phospholipid alterations.64 A number of 397 
studies have looked at adaptive changes in membrane lipids in response to solvent 398 
exposure. Studies by Junker and Ramos showed that a major adaptive change observed 399 
in the solvent resistant strain Pseudomonas putida DOT T1E in response to solvent is 400 
cis to trans isomerization in membrane lipids, predominantly in 401 
phosphatidylethanolamines, which counteracts the increase in membrane fluidity caused 402 
by toluene.67 The cis:trans ratio decreased from 7.5 to 1 when cells were grown in 1% 403 
toluene and changes were observed within 1 min of solvent exposure. The isomerase cti 404 
is located in periplasm where access to esterified phospholipids is possible and cis to 405 
trans isomerization is the main adaptive change in the short term, allowing cells to 406 
adapt immediately to environmental conditions in which a denser membrane packing is 407 
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a selective advantage. Cells gain time for de novo biosynthesis of membrane 408 
components as late as 15 min after solvent exposure. These changes include a shift in 409 
the ratio of saturated : unsaturated fatty acids and formation of C17 cyclopropane fatty 410 
acids, synthesis of solvent extrusion pumps, modifications in lipid polysaccharides and 411 
alterations in membrane protein content. 412 
 413 
ANOVA analysis of ATP concentrations prior to and post exposure to propranolol: We 414 
observed a significant rise in ATP concentration from 3.22 to 4.10 moles mg-1 dry 415 
weight cells in P. putida after 1 h  exposure to propranolol (Figure 6).  416 
 417 
The critical p-value (α) here was assumed to be 0.01. p-values were calculated in an 418 
ANOVA analysis for the null hypothesis that the medians of the 2 groups are equal: the 419 
p-value for controls prior to exposure vs. controls 1 h after exposure = 1.2 x 10-1 and the 420 
p- value for exposed cells prior to exposure vs. 1 h after exposure = 1.2 x 10-5, showing 421 
a significant difference at the α = 0.01 level in ATP concentration and energy demand in 422 
cells exposed to propranolol. 423 
 424 
(Figure 6) 425 
Conclusions 426 
In conclusion, we have presented a novel metabolomics approach to investigate the 427 
effect of human pharmaceuticals on the environmentally relevant microorganism P. 428 
putida KT2440 (UWC1).  Metabolic profiling using GC-MS coupled with univariate 429 
analysis and spring embedded correlation analysis was used to identify metabolites 430 
contributing to discrimination between cells exposed to the six drugs, and statistically 431 
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significant differences were observed for propranolol, diclofenac, ibuprofen and 432 
acetaminophen compared to untreated control cells.  433 
 434 
The concentrations of several metabolites were altered significantly on exposure to a 435 
number of the pharmaceuticals and may be considered biomarkers of abiotic stress. The 436 
endogenous, metabolites 129 and 130 were significantly reduced in concentration in P. 437 
putida exposed to propranolol, and 129 was reduced in cells exposed to diclofenac and 438 
mefenamic acid. Concentrations of trehalose and metabolite 47 were also significantly 439 
reduced on exposure to propranolol, ibuprofen, acetaminophen and atenolol. 440 
 441 
Six metabolites, 131, 134, 135, 139, 142, and 145, were raised in exposed cells from 442 
near or below the limit of detection in the control, and were not present in cells exposed 443 
to any other pharmaceutical in the study. Identification was not possible from the mass 444 
spectra which contained only low m/z ions.  Further work using 13C-labelled propranolol 445 
would determine whether propranolol is metabolized by KT2440, and whether these 446 
metabolites are endogenous metabolites or products of propranolol catabolism. 447 
 448 
We also note that the growth conditions we have used (viz. R2A medium) are 449 
considerably more nutrient rich that what would normally be expected in an 450 
environmental water sample or found within benthic-sediment ecology (although in the 451 
benthos or fresh water sediment one would expect the APIs to be more concentrated). 452 
Future work would be to investigate the use of the above markers of abiotic stress in a 453 
suitable ecosystem. Such an approach would involve target metabolite analysis 454 
encompassing significant sample clean up, specific metabolite extraction and targeted 455 
MS-MS for definitive metabolite identification and quantification. 456 
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 457 
 With respect to exposure to propranolol, FT-IR analysis revealed changes in fatty acids 458 
and protein structure while GC-MS revealed alterations in energy reserves, amino acids 459 
and some fatty acids. Measurement of ATP concentrations in P. putida exposed to 460 
propranolol showed an increased level of ATP in exposed cells. These alterations are in 461 
agreement with previous studies which have shown that lipids in the membrane are 462 
altered to try to retain membrane integrity, and that energy dependent efflux pumps are 463 
used to remove toxic compounds from the cell. Additional studies undertaken by us 464 
include further investigation of the phospholipid and fatty acid alterations in P. putida 465 
exposed to propranolol, and these will be reported elsewhere. 466 
 467 
We believe that this approach shows for the first time the value of developing a 468 
comprehensive metabolomics-based approach both for identifying discriminatory 469 
metabolites and their relationships to each other that reproducibly alter under abiotic 470 
stress.  Moreover, this approach allows the investigation of mechanisms of response to 471 
these stresses in environmentally relevant microbes and future work will investigate 472 
these effects in complex microbial communities. 473 
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Figure Legends 633 
 634 
Figure 1. 635 
a) Cross-validated PC-CVA models for the FT-IR spectra of P. putida exposed to the six 636 
pharmaceuticals. 637 
The FT-IR spectra were normalized and variables scaled to unit variance. 26 PCs (99.99% explained 638 
variance) and 6 CVs were used in the analysis trained on 4 class replicates (filled triangles). Test data (a 639 
fifth, unknown, class replicate) are marked with an asterisk (open triangles). Key; acetaminophen red, 640 
atenolol gold, diclofenac green, ibuprofen cyan, mefenamic acid blue, propranolol purple, control grey. 641 
Circles represent the 95% confidence limit from the group centres here constructed around each group 642 
mean by the χ2 distribution on two degrees of freedom. Cells exposed to propranolol and ibuprofen are 643 
separated along PC-CV1; those exposed to mefenamic acid are separated along PC-CV2. 644 
b) Examination of the loadings for PC-CV1 from the PC-CV analysis. 645 
Significant loadings with amplitude >2SD from the mean are shown in blue overlaid with the FT-IR 646 
spectrum for propranolol (green) and the FT-IR spectrum for the cells exposed to propranolol at 50µg 647 
mL-1 (blue). Several high loadings for PC-CV1 occur at significant wavenumbers for propranolol, the 648 
region corresponding to aliphatic C-H, and hence bacterial fatty acids, at 2919 and 2850cm-1, and the 649 
regions corresponding to the amide I bands in protein structures at 1655cm-1 ( α-helical structures), 1709, 650 
1659  and 1630cm-1 (β-sheet structures). 651 
Figure 2. PC-CVA model rebuilt using only absorbances at wavenumbers significant for bacterial 652 
fatty acids. The model used 12 PC scores (99.9% explained variance) and shows separation of P. putida 653 
exposed to propranolol (purple) from control cells (grey). Other exposures were not separated from the 654 
control, revealing that observed lipid alterations are specific to exposure to propranolol. 655 
 656 
Figure 3. Altered metabolites in P. putida exposed to propranolol. As a visual method for assessing 657 
significance of metabolites as discriminating biomarkers the area under the ROC curve (AUC) is plotted 658 
versus p-value from the ANOVA analysis. If a metabolite has an AUC =0.5 it is equally distributed 659 
between the two classes. A metabolite with an AUC = 1 is diagnostic of the class. Brown open circles 660 
denote fold increases, and grey open circles fold decreases, in metabolite concentration in exposed cells. 661 
Metabolites with an AUC > 0.7 and a p-value < 1.77 x 10-2 (the FWER threshold for a critical p-value 662 
equivalent to 0.05) are labeled. Some labels have been moved for clarity. Metabolites with an AUC > 663 
0.85 and a p-value < 1.77 x 10-2 were considered significant and selected for correlation analysis. 664 
 665 
Figure 4. Spring embedded correlation plots showing correlation between 43 metabolites a) in cells 666 
exposed to water and b) in cells exposed to propranolol.  Propranolol is correlated with energy-related 667 
metabolites: a sugar phosphate, trehalose and cellobiose; correlation is extended through metabolite 139, 668 
one of 3 metabolites with the lowest p-value whose concentration was raised from near the limit of 669 
detection, to succinic acid, a metabolite of the TCA cycle. In cells exposed to water trehalose and 670 
cellobiose are not correlated with succinic acid. Propranolol is also correlated with glycerol-3-phosphate, 671 
a precursor to the phosphatidyl group in glycerophospholipids. 672 
 673 
Figure 5. Alterations in the concentration of energy related metabolites in P. putida exposed to 674 
propranolol identified from the ANOVA analysis. Trehalose and cellobiose, which have a role as 675 
energy reserves, were reduced in concentration in exposed cells, while succinic acid and sugar phosphates 676 
( increased in concentration in exposed cells. 677 
 678 
Figure 6. Alterations in ATP concentration in P. putida exposed to propranolol. The median ATP 679 
concentration prior to and 1h after exposure in cells exposed to water as a control and cells exposed to 680 
propranolol.  p-values were calculated in an ANOVA analysis for the null hypothesis that the medians of 681 
the 2 groups are equal: the p-value for controls prior to exposure vs. controls 1 h after exposure =1.2 x10-1 682 
and the p- value for exposed cells prior to exposure vs. 1 h after exposure = 1.2 x10-5, showing a 683 
significant difference in ATP concentration and energy demand in cells exposed to propranolol. 684 
 685 
 686 
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